Radiation boosts CAR-T: new hope for tough lymphoma?
NCT ID NCT06768905
First seen Apr 17, 2026 · Last updated Jun 19, 2026 · Updated 9 times
Summary
This study tests whether giving a targeted radiation drug (Iomab-B) before standard CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 participants will receive the radiation dose followed by CAR-T cells. Researchers will monitor side effects and check if the cancer shrinks or disappears on PET/CT scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iomab-B (targeted radiation drug) followed by CAR-T cell therapy
What this could lead to
If it works, this combination could improve the effectiveness of CAR-T therapy for hard-to-treat lymphoma patients.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.